Summary： LncRNAH19 has been implicated as having both oncogenic and tumor suppression properties in cancer. LncRNAH19 transcripts also serve as a precursor for miR-675. However, it is unknown whether LncRNAH19 and mi...Summary： LncRNAH19 has been implicated as having both oncogenic and tumor suppression properties in cancer. LncRNAH19 transcripts also serve as a precursor for miR-675. However, it is unknown whether LncRNAH19 and miR-675 are involved in the migration and invasion of hepatocellular carcinoma （HCC） cells. The purpose of this study was to investigate the effect and mechanism of LncRNAH19 and miR-675 on migration and invasion of HCC cells. The migration and invasion of HCC cells were measured by Transwell migration and invasion assays after transfection of HCC cells with miR-675 inhibitors and LncRNAH19siRNA. The levels of LncRNAH19 and miR-675 were detected by quantitative reverse transcriptase real-time polymerase chain reaction （qRT-PCR）, and the protein expression of AKT, GSK-3[3 and Cdc25A by Western blotting analysis. The expression levels of LncRNAHI9 and miR-675 were higher in MHCC-97H cells than in L02, Huh-7 and HepG2 cells. Transwell migration assay revealed that the miR-675 inhibitor and LncRNAH19siRNA could significantly increase the migration of HCC cells （P〈0.01） as compared with the control group. Transwell invasion assay demonstrated that the miR-675 inhibitor and LncRNAH19siRNA could significantly increase the invasion of HCC cells （P〈0.01） as compared with the control group. Western blotting analy- sis showed that the expression levels of AKT and Cdc25A were significantly increased （P〈0.05）, and the expression level of GSK-313 was significantly decreased （P〈0.05） after treatment with miR-675 inhibitors and LncRNAH19siRNA as compared with the control group. These findings suggested that inhibition of LncRNAH 19 and miR-675 expression can promote migration and invasion of HCC cells via AKT/GSK-3[3/Cdc25A signaling pathway.展开更多
Backgroud and Objective Tumor metastasis is not only the malignant marker and characteristics of lung cancer, but also the main cause of failure to cure and lose their life of the
基金supported by grants from the National Natural Science Foundation of China(Nos.81071871,81101862 and 81172079)Natural Science Foundation of Guangdong Province,China(Nos.S2013010016831,and 10451008901006014)+4 种基金Science and Technology Planning Project of Guangdong Province,China(No.2009B030801014,2010B060500007 and 2011B060300012)the Foundation of the Health Department of Guangxi Province,China(No.Z2007212)the Foundation of Scientific Research and Technology Development Project of Guilin,China(key scientific and technological projects and trial production of new products,No.20110321)the Foundation of Scientific Research and Technology Development Project of Guangxi Province,China(No.GuiKeGong1355005-3-5)Foundation for Youth Teacher by Sun Yat-Sen University(No.11ykpy16)
文摘Summary： LncRNAH19 has been implicated as having both oncogenic and tumor suppression properties in cancer. LncRNAH19 transcripts also serve as a precursor for miR-675. However, it is unknown whether LncRNAH19 and miR-675 are involved in the migration and invasion of hepatocellular carcinoma （HCC） cells. The purpose of this study was to investigate the effect and mechanism of LncRNAH19 and miR-675 on migration and invasion of HCC cells. The migration and invasion of HCC cells were measured by Transwell migration and invasion assays after transfection of HCC cells with miR-675 inhibitors and LncRNAH19siRNA. The levels of LncRNAH19 and miR-675 were detected by quantitative reverse transcriptase real-time polymerase chain reaction （qRT-PCR）, and the protein expression of AKT, GSK-3[3 and Cdc25A by Western blotting analysis. The expression levels of LncRNAHI9 and miR-675 were higher in MHCC-97H cells than in L02, Huh-7 and HepG2 cells. Transwell migration assay revealed that the miR-675 inhibitor and LncRNAH19siRNA could significantly increase the migration of HCC cells （P〈0.01） as compared with the control group. Transwell invasion assay demonstrated that the miR-675 inhibitor and LncRNAH19siRNA could significantly increase the invasion of HCC cells （P〈0.01） as compared with the control group. Western blotting analy- sis showed that the expression levels of AKT and Cdc25A were significantly increased （P〈0.05）, and the expression level of GSK-313 was significantly decreased （P〈0.05） after treatment with miR-675 inhibitors and LncRNAH19siRNA as compared with the control group. These findings suggested that inhibition of LncRNAH 19 and miR-675 expression can promote migration and invasion of HCC cells via AKT/GSK-3[3/Cdc25A signaling pathway.
基金supported by grants from National Natural Sciences Foundation of China (to Qinghua ZHOU, No.3007033 )
文摘Backgroud and Objective Tumor metastasis is not only the malignant marker and characteristics of lung cancer, but also the main cause of failure to cure and lose their life of the
文摘目的研究中药降糖复方水提取物(WEJTD)对自发性2型糖尿病(T2DM)模型KK-Ay小鼠骨骼肌糖代谢PI3K/Akt信号通路的影响。方法将KK-Ay小鼠按随机数法随机分为5组:模型组、盐酸二甲双胍(MH,250 mg/kg)组和WEJTD低、中、高剂量(2、4、8 g/kg)组,C57BL/6J小鼠作为对照组,每天ig给药1次,共12周,对照组和模型组ig等体积蒸馏水。给药12周后,取小鼠血清,ELISA试剂盒法检测胰岛素水平;Trizol法提取肌肉组织中的RNA,荧光实时定量PCR(q RT-PCR)检测磷脂酰肌醇激酶-3(PI3K)、蛋白激酶B(Akt)、葡萄糖转运蛋白-4(GLUT-4)、糖原合成酶激酶-3β(GSK-3β)、糖原合成酶(GS)、胰岛素受体底物(IRS-1)m RNA水平。结果与模型组比较,WEJTD高、中剂量显著上调小鼠血清胰岛素水平、骨骼肌中IRS-1 m RNA水平(P<0.05、0.001);高、中、低剂量均显著下调骨骼肌中GSK-3βm RNA水平,显著上调PI3K、Akt、GLUT-4、GS m RNA水平(P<0.05、0.01、0.001)。结论中药降糖复方通过上调PI3K/Akt信号通路,减少糖原沉积,刺激骨骼肌中葡萄糖转运。
